NO20054647L - Anvendelse av isoquinolinderivater for behandling av kreft og map kinase relaterte sykdommer - Google Patents

Anvendelse av isoquinolinderivater for behandling av kreft og map kinase relaterte sykdommer

Info

Publication number
NO20054647L
NO20054647L NO20054647A NO20054647A NO20054647L NO 20054647 L NO20054647 L NO 20054647L NO 20054647 A NO20054647 A NO 20054647A NO 20054647 A NO20054647 A NO 20054647A NO 20054647 L NO20054647 L NO 20054647L
Authority
NO
Norway
Prior art keywords
treatment
map kinase
cancer
related diseases
isoquinoline derivatives
Prior art date
Application number
NO20054647A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054647D0 (no
Inventor
Timothy Michael Ramsey
Michael Lloyd Sabio
David Batt
Guldo Bold
Sunkyu Kim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20054647D0 publication Critical patent/NO20054647D0/no
Publication of NO20054647L publication Critical patent/NO20054647L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
NO20054647A 2003-03-11 2005-10-10 Anvendelse av isoquinolinderivater for behandling av kreft og map kinase relaterte sykdommer NO20054647L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11
PCT/EP2004/002460 WO2004080464A1 (en) 2003-03-11 2004-03-10 Use of isoquinoline derivatives for treating cancer and map kinase related diseases

Publications (2)

Publication Number Publication Date
NO20054647D0 NO20054647D0 (no) 2005-10-10
NO20054647L true NO20054647L (no) 2005-12-09

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054647A NO20054647L (no) 2003-03-11 2005-10-10 Anvendelse av isoquinolinderivater for behandling av kreft og map kinase relaterte sykdommer

Country Status (22)

Country Link
EP (1) EP1603566B1 (pt)
JP (1) JP2006519807A (pt)
KR (1) KR20050108383A (pt)
CN (1) CN1758910A (pt)
AT (1) ATE421324T1 (pt)
AU (1) AU2004218914A1 (pt)
BR (1) BRPI0408257A (pt)
CA (1) CA2518530A1 (pt)
DE (1) DE602004019193D1 (pt)
ES (1) ES2318276T3 (pt)
HR (1) HRP20050788A2 (pt)
IS (1) IS8064A (pt)
MA (1) MA27724A1 (pt)
MX (1) MXPA05009687A (pt)
NO (1) NO20054647L (pt)
PL (1) PL1603566T3 (pt)
PT (1) PT1603566E (pt)
RU (1) RU2325159C2 (pt)
TN (1) TNSN05223A1 (pt)
TW (1) TW200501955A (pt)
WO (1) WO2004080464A1 (pt)
ZA (1) ZA200506571B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902192B2 (en) 2003-05-15 2011-03-08 Arqule, Inc. Inhibitors of P38 and methods of using the same
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
EP2258704A1 (en) 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
MX2007011866A (es) * 2005-02-25 2007-10-10 Novartis Ag Combinacion farmaceutica de inhibidores de bcr-abl y raf.
SI1912949T1 (sl) * 2005-07-26 2011-12-30 Sanofi Sa Cikloheksilamin izokinolonski derivati kot inhibitorji Rho-kinaze
WO2008005910A2 (en) 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
CA2639416C (en) * 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Diagnostic test for susceptibility to b-raf kinase inhibitors
EP2724739B1 (en) 2009-07-30 2015-07-01 Tandem Diabetes Care, Inc. Portable infusion pump system
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CA2816088A1 (en) * 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
CN112384503A (zh) * 2018-07-02 2021-02-19 洛桑联邦理工学院(Epfl) 乳酸增强化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
EP1107964B8 (en) * 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
CO5200835A1 (es) * 1999-09-28 2002-09-27 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
WO2002060392A2 (en) * 2001-01-31 2002-08-08 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20030165873A1 (en) * 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system
US20050019424A1 (en) * 2001-12-21 2005-01-27 Adams Paul E. Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
TNSN05223A1 (en) 2007-06-11
ES2318276T3 (es) 2009-05-01
JP2006519807A (ja) 2006-08-31
DE602004019193D1 (de) 2009-03-12
BRPI0408257A (pt) 2006-03-07
HRP20050788A2 (en) 2006-12-31
KR20050108383A (ko) 2005-11-16
IS8064A (is) 2005-10-10
WO2004080464A1 (en) 2004-09-23
RU2005131168A (ru) 2006-05-27
ZA200506571B (en) 2006-07-26
CA2518530A1 (en) 2004-09-23
RU2325159C2 (ru) 2008-05-27
NO20054647D0 (no) 2005-10-10
ATE421324T1 (de) 2009-02-15
PT1603566E (pt) 2009-04-27
PL1603566T3 (pl) 2009-07-31
AU2004218914A1 (en) 2004-09-23
EP1603566A1 (en) 2005-12-14
MA27724A1 (fr) 2006-01-02
TW200501955A (en) 2005-01-16
CN1758910A (zh) 2006-04-12
EP1603566B1 (en) 2009-01-21
MXPA05009687A (es) 2005-10-20

Similar Documents

Publication Publication Date Title
SG132672A1 (en) 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
NO20054647D0 (no) Anvendelse av isoquinolinderivater for behandling av kreft og map kinase relaterte sykdommer
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO330981B1 (no) Indol- eller benzimidazolderivater for modulering av IkB-kinase, fremgangsmate for fremstilling av disse, legemiddel og anvendelse av forbindelsene
DK0711282T3 (da) Forbindelser som PDE IV og TNF inhibitorer
EA200700321A1 (ru) Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
BRPI0411365A (pt) derivados de aminopiridina
EA200801037A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
CY1108267T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
ATE362929T1 (de) Pyridinderivate als inhibitoren der raf-kinase
NO20026242D0 (no) Syntesemetoder for aplidin og nye antitumorale derivater, metoder for fremstilling og anvendelse av disse
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
ATE443717T1 (de) Metastin derivate und ihre verwendung
NO20073839L (no) Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
ATE295365T1 (de) Pyridinderivative als angiogenese- und/oder vegf- rezeptor-tyrosinkinase-inhibitoren
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
NO20050640L (no) Rutenium anticancer komplekser
ATE482955T1 (de) Azabicyclooctan-3-onderivate und deren verwendung
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
NO20055650L (no) Ruteinum (II)-komplekser for behandling av tumorer
HUP0402639A2 (hu) Szubsztituált akriloil-disztamicin-származékokat és protein kináz (szerin/treonin kináz) inhibitorokat tartalmazó tumorellenes kombinációs készítmény és alkalmazása
DE60120398D1 (de) Imidazopyridin-8-one
UY27768A1 (es) 2-(2,6- diclorofenil)-diarilimidazoles

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application